Benefits of Dual I-O Therapy in Metastatic Uveal Melanoma

Conference Correspondent —December 15, 2021
Sanjiv S. Agarwala, MD
Professor
Temple University School of Medicine
Philadelphia, PA

Dr Sanjiv Agarwala analyzes data from 2 studies showing that the first-line combination of nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses, as well as improved overall survival compared with monotherapy, in patients with metastatic uveal melanoma.

Related Articles
Phase 2 Study of Nivolumab plus Ipilimumab in Metastatic Uveal Melanoma
Conference Correspondent
Nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses for patients with metastatic uveal melanoma.
Phase 2 Trial of Nivolumab plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: Spanish Multidisciplinary Melanoma Group (GEM-1402)
Conference Correspondent
Nivolumab plus ipilimumab demonstrated improvement in overall survival for patients with metastatic uveal melanoma.
Relatlimab plus Nivolumab versus Nivolumab Alone in First-Line Advanced Melanoma: Primary Results from RELATIVITY-047
Conference Correspondent
First-line treatment with relatlimab plus nivolumab demonstrated a statistically significant progression-free survival benefit compared with nivolumab monotherapy in patients with advanced melanoma.
Last modified: December 16, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code